HomeMarketsSharesCarl Zeiss Meditec AG

Trade Carl Zeiss Meditec AG - AFX CFD

Market is not available at the momentMarket information is presented
as of 2026-10-16T15:26:10+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.14
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
€1,000.00
Overnight funding adjustment
Charges from full value of position
-0.01802 %
(-€3.60)

Trade size with leverage ~ €20,000.00

Money from leverage ~ $€19,000.00


-0.01802%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
€1,000.00
Overnight funding adjustment
Charges from full value of position
-0.00421 %
(-€0.84)

Trade size with leverage ~ €20,000.00

Money from leverage ~ $€19,000.00


-0.00421%
Overnight funding adjustment time21:00 (UTC)
CurrencyEUR
Min traded quantity0.1
Margin5.00%
Stock exchangeGermany
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close32.84
Open32.62
1-Year Change-27.43%
Day's Range32.62 - 33.28

Trade Carl Zeiss Meditec AG - AFX

About Carl Zeiss Meditec AG

Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.

Financial summary

BRIEF: For the three months ended 31 December 2021, Carl Zeiss Meditec AG revenues increased 11% to EUR410.2M. Net income decreased 18% to EUR37.9M. Revenues reflect Ophthalmic Devices segment increase of 10% to EUR310.9M, Microsurgery segment increase of 16% to EUR99.3M, Asia/Pacific Region segment increase of 15% to EUR181.5M, EMEA segment increase of 5% to EUR114.1M.

Equity composition

10/2006, Rights Issue, 3 new shares for every 2 shares held @ EUR 10.1 (Factor: 1.369066).

Latest shares articles

BAE Systems stock forecast
BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026
TAURON stock forecast
TAURON stock forecast: H1 earnings
TAURON is a Polish energy group. In the first half of 2026, revenue was broadly flat, while EBITDA and net profit fell amid higher CO2 allowance costs and coal consumption. Explore third-party analyst targets and technicals. Past performance is not a reliable indicator of future results.
12:04, 12 October 2026
Puma stock forecast
Puma stock forecast: Anta stake deal cleared
Puma is a German sportswear company. Chinese regulators have cleared Anta Sports’ proposed acquisition of an approximately 29% stake, with completion expected before the end of 2026. Explore third-party PUM price targets. Past performance is not a reliable indicator of future results.
10:19, 12 October 2026
Dino Polska stock forecast
Dino Polska stock forecast: H1 sales growth slows
Dino Polska is a Polish grocery retailer. In H1 2026, revenue rose 12.5% year on year to 18.0bn PLN, while like-for-like sales growth slowed to 2.2%. Explore third-party DNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
08:27, 12 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready